Literature DB >> 34737121

NAFLD as a continuous driver in the whole spectrum of vascular disease.

Wei Li1, Jiayi Liu1, Jingjing Cai2, Xiao-Jing Zhang3, Peng Zhang3, Zhi-Gang She4, Shaoze Chen5, Hongliang Li6.   

Abstract

Vascular disease is the prime determinant to cardiovascular morbidities and mortalities, which comprises the early vascular damage and subsequent cardiovascular events. Non-alcohol Fatty Liver Disease (NAFLD) is a systemic metabolic disorder that drives the progression of vascular disease through complex interactions. Although a causal relationship between NAFLD and cardiovascular disease (CVD) has not been established, a growing number of epidemiological studies have demonstrated an independent association between NAFLD and early vascular disease and subsequent cardiovascular events. In addition, mechanistic studies suggest that NAFLD initiates and accelerates vascular injury by increasing systemic inflammation and oxidative stress, impairing insulin sensitivity and lipid metabolism, and modulating epigenetics, the intestinal flora and hepatic autonomic nervous system; thus, NAFLD is a putative driving force for CVD progression. In this review, we summarize the clinical evidence supporting the association of NAFLD with subclinical vascular disease and cardiovascular events and discuss the potential mechanisms by which NAFLD promotes the progression of vascular disease.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular event; Early vascular damage; Endothelial dysfunction; NAFLD; Vascular health

Mesh:

Year:  2021        PMID: 34737121     DOI: 10.1016/j.yjmcc.2021.10.007

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  3 in total

1.  A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease.

Authors:  Xiaozhi Hu; Jiajun Fan; Qianqian Ma; Lei Han; Zhonglian Cao; Caili Xu; Jingyun Luan; Guangjun Jing; Yanyang Nan; Tao Wu; Yuting Zhang; Hanqi Wang; Yuanzhen Zhang; Dianwen Ju
Journal:  J Nanobiotechnology       Date:  2022-05-19       Impact factor: 9.429

Review 2.  Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes.

Authors:  Věra Čertíková Chábová; Oskar Zakiyanov
Journal:  Int J Mol Sci       Date:  2022-03-04       Impact factor: 5.923

3.  The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China.

Authors:  Fang Lei; Juan-Juan Qin; Xiaohui Song; Ye-Mao Liu; Ming-Ming Chen; Tao Sun; Xuewei Huang; Ke-Qiong Deng; Xiuran Zuo; Dongai Yao; Li-Juan Xu; Huiming Lu; Gang Wang; Feng Liu; Lidong Chen; Jie Luo; Jiahong Xia; Lin Wang; QiongYu Yang; Peng Zhang; Yan-Xiao Ji; Xiao-Jing Zhang; Zhi-Gang She; Qiang Zeng; Hongliang Li; Jingjing Cai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-27       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.